JP5914465B2 - 止血剤組成物 - Google Patents
止血剤組成物 Download PDFInfo
- Publication number
- JP5914465B2 JP5914465B2 JP2013510679A JP2013510679A JP5914465B2 JP 5914465 B2 JP5914465 B2 JP 5914465B2 JP 2013510679 A JP2013510679 A JP 2013510679A JP 2013510679 A JP2013510679 A JP 2013510679A JP 5914465 B2 JP5914465 B2 JP 5914465B2
- Authority
- JP
- Japan
- Prior art keywords
- gelatin
- composition
- hemostatic agent
- recombinant
- cross
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 35
- 230000002439 hemostatic effect Effects 0.000 title description 13
- 108010010803 Gelatin Proteins 0.000 claims description 104
- 229920000159 gelatin Polymers 0.000 claims description 103
- 235000019322 gelatine Nutrition 0.000 claims description 103
- 235000011852 gelatine desserts Nutrition 0.000 claims description 103
- 239000008273 gelatin Substances 0.000 claims description 92
- 229940030225 antihemorrhagics Drugs 0.000 claims description 30
- 239000002874 hemostatic agent Substances 0.000 claims description 30
- 238000004132 cross linking Methods 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 11
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- IQQYLBIFFAFHPD-UHFFFAOYSA-N 3-(iminomethylideneamino)propan-1-amine;hydrochloride Chemical compound Cl.NCCCN=C=N IQQYLBIFFAFHPD-UHFFFAOYSA-N 0.000 claims 1
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 claims 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 31
- 108010035532 Collagen Proteins 0.000 description 28
- 102000008186 Collagen Human genes 0.000 description 28
- 229920001436 collagen Polymers 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 10
- 229960002897 heparin Drugs 0.000 description 10
- 229920000669 heparin Polymers 0.000 description 10
- 230000023555 blood coagulation Effects 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 230000035602 clotting Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 101800003265 Beta-thromboglobulin Proteins 0.000 description 4
- 102000007329 beta-Thromboglobulin Human genes 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 3
- 230000010118 platelet activation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102100030411 Neutrophil collagenase Human genes 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101710137510 Saimiri transformation-associated protein Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 101001011890 Xenopus laevis Matrix metalloproteinase-18 Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001718 carbodiimides Chemical group 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101001011896 Homo sapiens Matrix metalloproteinase-19 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 102100030218 Matrix metalloproteinase-19 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102000036436 Metzincins Human genes 0.000 description 1
- 108091007161 Metzincins Proteins 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 1
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 102000053148 human MMP1 Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- -1 serine amino acids Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/104—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0038—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Description
「含む “comprising” 」という用語は、記載した部分、工程または成分の存在を特定すると解釈すべきであるが、一以上の追加の部分、工程または成分を排除しない。
本発明は、止血剤として使用するために少なくとも7の等電点を示す架橋ゼラチンを含む組成物を提供する。
ゼラチンおよび架橋ゼラチンの等電点は、ゼラチンのアミノ酸組成に基づいて算出する。
別の好適実施態様では、組成物中の組み換えゼラチンは、10g未満のブルーム強度を示す非ゲル化性組み換えゼラチンである。
本発明の架橋止血組成物の重要な特徴は、当該組成物は生分解性であり、それを除去するのに侵襲性外科的方法を要しない。
本発明の組成物は当業者に公知であるいずれかの方法により製造できる。
(a)ゼラチン、好ましくは、組み換えゼラチンを水中に、少なくとも0.1、0.5、1,3、6、12、24〜35重量容量%溶解させること;
(b)得られた溶液を凍結乾燥させること;
(c)少なくとも0.1、0.25、0.5、1、1.5、2、2.5〜10重量%の濃度のカルボジイミド架橋剤、好ましくはEDCを含む極性溶媒、好ましくは、エタノール中で、凍結乾燥させた物質を、少なくとも10分で最高24時間までの間で架橋させること;
を含む方法により製造される。
(a)ゼラチン、好ましくは、組み換えゼラチンを水中に、少なくとも0.1、0.5、1,3、6、12、24〜35重量容量%溶解させること、
(b)得られた溶液(a)のpHを、3〜6、より好ましくは、4〜5そしてさらにより好ましくは4.5に調整すること、
(c)少なくとも0.6、1.2、3.6、7.2、12.5のモル比で少なくとも10分で最高24時間、EDC/リシン残基中のEDCを加えることにより、得られた溶液を架橋させること;
(d)架橋済みゼラチンヒドロゲルを超トラックスし(ultrauxing)、水で濯ぐこと;
(e)得られた架橋済みゼラチンヒドロゲル粒子を凍結乾燥し、粉末を得ること;
を含む方法により好適に製造できる。
図1は、血液試料の血小板数における種々の架橋済みゼラチンの影響を示し;
図2は、架橋済みゼラチンと接触後の血液試料のβ−トロンボグロブリンの量を示し;
図3は、種々の架橋済みゼラチンの存在下におけるトロンビン−抗トロンビンコンプレックスの形成を示し;
図4は、種々の架橋済みゼラチンの存在下の血液凝固時間を示し;
図5は、種々の架橋済みゼラチンの存在下の血液凝固を妨げるのに必要なヘパリンの最小量を示す。
国際特許出願WO2008103041号に記載されている通りにして製造した組み替えゼラチンCBE3を使用した。架橋手順は下記の通りである:すなわち、CBE3溶液(1%)をEDC架橋のためpH4でまたはヘキサメチレンジイソシアナート(HMDIC)もしくは脱ヒドロ化熱処理架橋(DHT)のためpH10で緩衝化させ、次いで、凍結乾燥させた。凍結乾燥させたCBE3溶液を、無水エタノール中に溶解させたEDC(0.25%)またはHMDIC(0.0075%)と24時間反応させることにより架橋した。反応の最後にエタノールを室温で減圧乾燥により除去した。DHT架橋は、凍結乾燥させたCBE3を1夜80℃で熱処理をし、次いで、8時間160℃で減圧条件下熱処理することにより行った。
種々の架橋済みゼラチンの止血作用を「動的チャンドラーループ法」(Chandler AB等、1958、Lab Invest,7:p110−114)を使用して試験した。この試験は、血液凝固モデルとして回転ミキサー中の管内部の止血材料を使用する。このモデルは、ヒト止血系の異なるカスケード反応(凝固、細胞変化、血小板および補体活性化)を開始するため人工表面の能力を研究する働きをする。
図1
EDC架橋済み組み換えゼラチンは血小板の減少をもたらす。血液と人工表面との接触は、血小板機能の連続した損失を伴う血小板の活性化と変性をもたらす。血小板量の大きな減少は、高いトロンボゲン形成能に関連する。顕著な減少は、EDCを用いて架橋した組み換えゼラチンで観察された。その他の架橋方法では減少は観察されなかった。
図2
動的チャンドラーループ実験は、EDC架橋済み組み換えゼラチンが血小板の活性化をもたらすことを示す。表面への接着性による血小板の活性は、4段階の事象をもたらす:すなわち、偽足の形成を伴う形態変化、接着、凝固および血小板因子のα−顆粒(血小板因子4、β−トロンボグロブリン、等)外への放出である。血漿中のβ−トロンボグロブリンの濃度は血小板活性化度に一致する。
図3
動的チャンドラーループ実験は、EDC架橋済み組み換えゼラチンがトロンビン−抗トロンビンコンプレックスの形成をもたらすことを示す。トロンビン−抗トロンビンコンプレックス(TAT)は、トロンビン形成の感受性高いマーカーであり、したがって、凝固活性検出の卓越したマーカーでもある。TATコンプレックスは、生成したトロンビンと抗トロンビンIIIとの結合後に形成される。極度に高いTAT濃度は、特に、高ヘパリン濃度(5IU/ml)を用いる実験におけるゼラチンの強力な凝血促進能に反映する。
凝固速度
図4
凝固メーター(Biomatic 2000,Sarstedt)を使用して凝固速度を測定した。当該凝固メーターは、試料にする特定の光波長の試料の吸光度を測定し、吸光度が経過時間と共にどのように変化するかによる光学的に凝固の過程をモニターする。上述したようにして4人の健常なボランティアから血液を採取した。これらの試料にヘパリンを加えなかった。表面積50cm2の架橋済みゼラチン止血剤を血液に加えた。最も早い凝固時間をEDC架橋済み組み換えゼラチンで検出し、それは強力な凝固促進能を示す。
動的チャンドラーループ実験に記載されている通りにして提供者から血液を採取した。Heparin−Natrium−25000−ratiopharm(Ratiopharm GmbH,Ulm,Germany)を、1、3または5 IU/ml濃度で、12.5ml血液に加えた。血液を50cm2止血剤試料と共にチャンドラーループシステム中で1時間にわたって37℃で回転させ、その後、肉眼で目視できる血栓形成を防止するためにヘパリンの最小濃度を決定した。肉眼的に目視できる血液凝固の形成を防止するために必要なヘパリンの濃度は、止血剤の性能を示す。1 IU/mlヘパリン濃度は、アミン−アミン架橋したゼラチンに必要であるが、EDC架橋済み組み換えゼラチンは、このヘパリン濃度で血液凝固を依然として引き起こす。ヘパリン濃度を3 UL/mlまで増加させても、EDC架橋済み組み換えゼラチンを用いると依然として血液凝固を阻止しなかった。EDC架橋済み組み換えゼラチンを加えた血液中の血栓形成を防止するのに、5 UL/mlヘパリンの添加が必要だった。
Claims (9)
- 止血剤として使用するための、少なくとも7の等電点を有する架橋済みゼラチンを含む組成物であって、ゼラチンが、少なくとも一つのRGDモチーフを含み、ゼラチンを1−エチル−3−[3−ジメチルアミノプロピル]カルボジイミド塩酸塩(EDC)を使用して架橋する、当該組成物。
- 架橋しようとするゼラチンの等電点が架橋前に少なくとも7である、請求項1に記載の止血剤として使用するための組成物。
- 架橋しようとするゼラチンの等電点が架橋前に少なくとも9である、請求項1または2に記載の止血剤として使用するための組成物。
- 架橋後の架橋済みゼラチンの等電点が少なくとも9である、請求項1〜3のいずれかに記載の止血剤として使用するための組成物。
- 前記組み換えゼラチンは、ヒドロキシプロリン残基およびヒドロキシリジン残基を含まない、請求項4に記載の止血剤として使用するための組成物。
- 前記組み換えゼラチンが、架橋前、少なくとも0.40ミリモル/gリシン残基を含む、請求項1〜5のいずれかに記載の止血剤として使用するための組成物。
- 前記組み換えゼラチンが、少なくとも1.0であるアルギニンおよびリシンの総数とグルタミンおよびアスパラギンアミノ酸残基の総数との間の比を含む、請求項1〜6のいずれかに記載の止血剤として使用するための組成物。
- 前記組み換えゼラチンの分子量が少なくと50kDaである、請求項1〜7のいずれかに記載の止血剤として使用するための組成物。
- 請求項1〜8のいずれかに記載の組成物の製造方法であって、
(a) 水中に少なくとも0.1〜35重量容量%のゼラチンを溶解させること;
(b) 得られた溶液を凍結乾燥させること;
(c) 得られた凍結乾燥物を、少なくとも0.1〜10重量%濃度の1−エチル−3−[3−ジメチルアミノプロピル]カルボジイミド塩酸塩(EDC)を含む極性溶媒中で架橋すること、ここで、架橋は少なくとも10分〜24時間まで行うこと
を含む上記組成物の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1008404.4 | 2010-05-20 | ||
GBGB1008404.4A GB201008404D0 (en) | 2010-05-20 | 2010-05-20 | Hemostatic compositions |
PCT/GB2011/050689 WO2011144916A1 (en) | 2010-05-20 | 2011-04-07 | Hemostatic compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013526564A JP2013526564A (ja) | 2013-06-24 |
JP5914465B2 true JP5914465B2 (ja) | 2016-05-11 |
Family
ID=42341033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013510679A Active JP5914465B2 (ja) | 2010-05-20 | 2011-04-07 | 止血剤組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20130066049A1 (ja) |
EP (1) | EP2571494B1 (ja) |
JP (1) | JP5914465B2 (ja) |
DK (1) | DK2571494T3 (ja) |
GB (1) | GB201008404D0 (ja) |
WO (1) | WO2011144916A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201018044D0 (en) | 2010-10-26 | 2010-12-08 | Fujifilm Mfg Europe Bv | Non-natural gelatin-like proteins with enhanced functionality |
US10765774B2 (en) | 2013-07-09 | 2020-09-08 | Ethicon, Inc. | Hemostatic pad assembly kit and method |
US11679177B2 (en) | 2017-08-08 | 2023-06-20 | Baxter International Inc. | Polymeric compositions, delivery devices, and methods |
CN114681662A (zh) * | 2020-12-30 | 2022-07-01 | 江苏江山聚源生物技术有限公司 | 重组胶原蛋白在制备止血材料中的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2465357A (en) | 1944-08-14 | 1949-03-29 | Upjohn Co | Therapeutic sponge and method of making |
US3364200A (en) | 1960-03-28 | 1968-01-16 | Johnson & Johnson | Oxidized cellulose product and method for preparing the same |
US3742955A (en) | 1970-09-29 | 1973-07-03 | Fmc Corp | Fibrous collagen derived product having hemostatic and wound binding properties |
US4215200A (en) | 1978-10-02 | 1980-07-29 | Cornell Research Foundation, Inc. | Chemically and enzymatically modified collagen hemostatic agent |
US6063061A (en) * | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US7871637B2 (en) * | 1996-08-27 | 2011-01-18 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
US7435425B2 (en) * | 2001-07-17 | 2008-10-14 | Baxter International, Inc. | Dry hemostatic compositions and methods for their preparation |
NL1007908C2 (nl) | 1997-12-24 | 1999-06-25 | Fuji Photo Film Bv | Zilverhalide-emulsies met recombinant collageen die geschikt zijn voor fotografische toediening alsmede de bereiding daarvan. |
MXPA01001510A (es) | 1998-08-10 | 2003-08-20 | Fibrogen Inc | Composiciones hemostaticas de colageno tipo i y tipo iii para usarse como sellador vascular y vendaje para heridas. |
DE69940802D1 (de) | 1998-12-23 | 2009-06-10 | Fujifilm Mfg Europe Bv | Silberhalogenidemulsionen, die rekombinante gelatineartige Proteine enthalten |
JP4597454B2 (ja) | 1999-11-12 | 2010-12-15 | ファイブローゲン、インコーポレーテッド | 組換えゼラチン |
EP1238675A1 (en) | 2001-03-06 | 2002-09-11 | Fuji Photo Film B.V. | Recombinant gelatin-like proteins for use as plasma expanders |
US20060147501A1 (en) | 2003-02-28 | 2006-07-06 | Hillas Patrick J | Collagen compositions and biomaterials |
EP1608681B1 (en) | 2003-03-28 | 2008-06-04 | FUJIFILM Manufacturing Europe B.V. | Rgd-enriched gelatine-like proteins with enhanced cell binding |
GB2414021A (en) * | 2004-05-10 | 2005-11-16 | Johnson & Johnson Medical Ltd | Absorbable haemostatic materials |
GB2433029A (en) * | 2005-12-09 | 2007-06-13 | Ethicon Inc | Wound dressings comprising oxidized cellulose and human recombinant collagen |
EP1961414A1 (en) * | 2007-02-21 | 2008-08-27 | FUJIFILM Manufacturing Europe B.V. | A controlled release composition comprising a recombinant gelatin |
WO2008103041A1 (en) * | 2007-02-21 | 2008-08-28 | Fujifilm Manufacturing Europe B.V. | Recombinant gelatins |
US9629798B2 (en) * | 2008-04-03 | 2017-04-25 | Mallinckrodt Pharma Ip Trading D.A.C. | Hemostatic microspheres |
JP2010053080A (ja) * | 2008-08-28 | 2010-03-11 | Fujifilm Corp | キトサンとコラーゲンを含む構造体 |
US20110182960A1 (en) * | 2008-10-02 | 2011-07-28 | Elisabeth Marianna Wilhelmina Maria Van Dongen | Antimicrobial Coating |
-
2010
- 2010-05-20 GB GBGB1008404.4A patent/GB201008404D0/en not_active Ceased
-
2011
- 2011-04-07 DK DK11714599.5T patent/DK2571494T3/en active
- 2011-04-07 WO PCT/GB2011/050689 patent/WO2011144916A1/en active Application Filing
- 2011-04-07 JP JP2013510679A patent/JP5914465B2/ja active Active
- 2011-04-07 EP EP11714599.5A patent/EP2571494B1/en active Active
- 2011-04-07 US US13/698,441 patent/US20130066049A1/en not_active Abandoned
-
2015
- 2015-09-10 US US14/850,101 patent/US20160000962A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB201008404D0 (en) | 2010-07-07 |
JP2013526564A (ja) | 2013-06-24 |
EP2571494A1 (en) | 2013-03-27 |
US20130066049A1 (en) | 2013-03-14 |
US20160000962A1 (en) | 2016-01-07 |
DK2571494T3 (en) | 2017-03-13 |
EP2571494B1 (en) | 2017-01-11 |
WO2011144916A1 (en) | 2011-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6235104B2 (ja) | 止血組成物 | |
Kumar et al. | A nanostructured synthetic collagen mimic for hemostasis | |
RU2661036C2 (ru) | Средство для гемостатической обработки раны | |
CN103687631B (zh) | 促凝血肽及其衍生物以及它们的用途 | |
TWI436793B (zh) | 快速作用之乾密封膠及其使用和製造方法 | |
JP4025897B2 (ja) | コラーゲンの調製 | |
Seon et al. | Functional improvement of hemostatic dressing by addition of recombinant batroxobin | |
JP2023118919A (ja) | 止血材 | |
JP2017538751A (ja) | 流動性止血組成物 | |
Krishnan et al. | Comparative evaluation of absorbable hemostats: advantages of fibrin-based sheets | |
US20170258954A1 (en) | Flowable collagen-based hemostat and methods of use | |
JP2005517638A (ja) | 保存安定性のあるフィブリンシーラント | |
JP7223447B2 (ja) | 止血用組成物及びこれを含む容器 | |
JP4468577B2 (ja) | 完全に組換え体の組織シーラント組成物 | |
JP5914465B2 (ja) | 止血剤組成物 | |
JPWO2008117746A1 (ja) | 固体状フィブリノゲン製剤 | |
AU2012318259A1 (en) | Hemostatic compositions | |
JP2024056090A (ja) | 組織癒着を防止するための低濃縮タンパク質組成物 | |
Ghosh et al. | Bioinspired non-immunogenic multifunctional sealant for efficient blood clotting and suture-free wound closure | |
KR20050084954A (ko) | 트롬빈-고정화 생체흡수성 합성 부직포 | |
Xu et al. | Biomimetic peptide nanoparticles participate in natural coagulation for hemostasis and wound healing | |
RU2744694C2 (ru) | Гемостатические композиции | |
Silcock | Collagen-based dressings as therapeutic agents for wound healing | |
Anitua et al. | Biochemical and biomechanical characterization of an autologous protein-based fibrin sealant for regenerative medicine | |
WEISEL et al. | 18. FIBRINOGEN AND FIBRIN: CHARACTERIZATION, PROCESSING AND MEDICAL APPLICATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140404 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151216 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160404 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5914465 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |